Hemoglobin Derivative Co-Conjugated with FA-PEG and Alkoxy-PEG
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current blood substitutes, particularly hemoglobin-based oxygen carriers (HBOCs), face challenges such as short intravascular half-life, toxicity, and limited oxygen-carrying capacity, which hinder their effectiveness as safe and durable alternatives to human blood.
Innovation Solution
A hemoglobin derivative is developed by conjugating hemoglobin (Hb) or crosslinked hemoglobin (xHb) with fatty acid-PEG (FA-PEG) derivatives and alkoxy-PEG derivatives, enhancing stability, intravascular retention, and oxygen-carrying capability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If native hemoglobin is used as a blood substitute, then oxygen-carrying capability is provided, but intravascular half-life is short and toxicity occurs
Solution Approach 1:
The patent applies parameter changes by chemically modifying hemoglobin through conjugation with PEG derivatives and fatty acids, altering its molecular weight, surface properties, and stability parameters to achieve extended intravascular half-life and reduced toxicity while maintaining oxygen-carrying function
Solution Approach 2:
The patent creates a composite material by conjugating hemoglobin with polyethylene glycol (PEG) derivatives and fatty acid chains, forming a hybrid molecule that combines the oxygen-carrying capability of hemoglobin with the stabilizing and protective properties of PEG and fatty acid moieties
2Stability of the object's composition
If hemoglobin is modified to increase molecular weight and stabilize structure, then intravascular retention is improved, but complexity of modification increases
Solution Approach 1:
The patent applies segmentation by dividing the modification process into distinct functional components: PEG conjugation for stability enhancement, fatty acid linkage for intravascular retention, and crosslinking for structural stabilization, allowing each modification to be optimized independently
Solution Approach 2:
The patent uses crosslinking agents as intermediaries to stabilize the hemoglobin structure without directly modifying the hemoglobin molecule itself, thereby achieving structural stability while minimizing modification complexity
3Reliability
If multiple conjugation strategies are applied to hemoglobin, then intravascular retention and stability are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent merges multiple conjugation strategies into a single comprehensive modification approach, combining PEG conjugation, fatty acid linkage, and crosslinking in one process flow to achieve enhanced intravascular retention while managing manufacturing complexity through integrated processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hemoglobin derivative exhibits improved non-toxicity, long-term stability, and extended intravascular retention, making it a viable and effective blood substitute for various medical applications.
Implementation Method 1
hemoglobin (Hb) or crosslinked hemoglobin (xHb) is conjugated with fatty acid-PEG (FA-PEG) derivatives and alkoxy-PEG derivatives
Data Source
AI summary
The invention relates to hemoglobin derivative, particularly hemoglobin which is co-conjugated with both fatty acid-linked polyethylene glycol (FA-PEG) derivatives and alkoxy polyethylene glycol (alkoxy-PEG) derivatives, and a method for making such hemoglobin derivative. Various embodiments of the invention include crosslinked hemoglobin which is co-conjugated with both FA-PEG derivatives and alkoxy-PEG derivatives. Such hemoglobin derivative according to the invention exhibit non-toxicity and extended intravascular retention time.